Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
Relapsing multiple sclerosis
adverse event
anti-glomerular basement membrane antibodies
autoimmune hepatitis
cladribine tablets
secondary autoimmunity
thrombocytopenia
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
pubmed:
25
6
2021
medline:
26
10
2021
entrez:
24
6
2021
Statut:
ppublish
Résumé
Oral cladribine is an approved disease-modifying drug for the treatment of relapsing multiple sclerosis. In controlled clinical trials as well as in post marketing safety assessments, autoimmune conditions have not yet been reported as a specific side effect of cladribine. Here, we report a case of anti-glomerular basement membrane antibody-mediated glomerulonephritis that occurred shortly after the fourth cladribine treatment cycle. Neurologists should be attentive to the development of secondary autoimmunity in cladribine-treated patients.
Sections du résumé
BACKGROUND
Oral cladribine is an approved disease-modifying drug for the treatment of relapsing multiple sclerosis. In controlled clinical trials as well as in post marketing safety assessments, autoimmune conditions have not yet been reported as a specific side effect of cladribine.
OBJECTIVE AND RESULTS
Here, we report a case of anti-glomerular basement membrane antibody-mediated glomerulonephritis that occurred shortly after the fourth cladribine treatment cycle.
CONCLUSION
Neurologists should be attentive to the development of secondary autoimmunity in cladribine-treated patients.
Identifiants
pubmed: 34165361
doi: 10.1177/13524585211022719
pmc: PMC8521349
doi:
Substances chimiques
Immunosuppressive Agents
0
Cladribine
47M74X9YT5
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1960-1964Références
Am J Pathol. 1998 Jun;152(6):1541-8
pubmed: 9626058
Lancet. 1992 Oct 17;340(8825):952-6
pubmed: 1357355
Mult Scler Relat Disord. 2019 May;30:176-186
pubmed: 30785074
N Engl J Med. 2010 Feb 4;362(5):416-26
pubmed: 20089960
Nat Immunol. 2012 May 27;13(7):667-73
pubmed: 22634866
Mult Scler. 2018 Oct;24(12):1594-1604
pubmed: 28870107
Mult Scler Relat Disord. 2019 Apr;29:168-174
pubmed: 30885375
Hum Immunol. 2016 Oct;77(10):921-929
pubmed: 27343993
F1000Res. 2017 Mar 29;6:391
pubmed: 28408984
Lancet Neurol. 2014 Mar;13(3):257-67
pubmed: 24502830
Mult Scler Relat Disord. 2019 Apr;29:157-167
pubmed: 30885374
Nephrol Dial Transplant. 2018 Feb 1;33(2):196-202
pubmed: 28459999
J Am Soc Nephrol. 2013 Feb;24(3):419-31
pubmed: 23411782
Mult Scler. 2011 May;17(5):578-93
pubmed: 21228029